Introduction {#Sec1}
============

Type 1 diabetes (T1D) is characterized by insulin deficiency and resulting dysglycemia^[@CR1]^. Recently, metabolomic analyses have been used to study metabolic changes in T1D patients prior to autoantibody (AAb) development^[@CR2]^, associated with AAb seroconversion^[@CR3]^, as well as with symptomatic T1D and glycemic control^[@CR4]--[@CR6]^. Specifically, metabolomic alterations documented prior to AAb development in children that later developed T1D include decreased succinic acid, phosphatidylcholine, and citric acid at birth alongside increased pro-inflammatory lysophosphatidylcholine months prior to seroconversion^[@CR2]^. AAb positivity is associated with low methionine and hydroxyproline, with high odd-chain triglycerides and polyunsaturated fatty acids (FA) containing phospholipids^[@CR3]^. Beyond this, T1D patients with poor glycemic control demonstrate decreased glycolytic metabolites and elevated carbohydrate metabolites, branched chain amino acids (AA), short chain FA, and ketoacids^[@CR4]^. Interestingly, many of these metabolic perturbations are also present in T1D patients with good glycemic control^[@CR4]^.

Canine diabetes has multiple parallels to human T1D, including a requirement for lifelong insulin therapy in most cases, the development of ketoacidosis at diagnosis or during therapy^[@CR7]^, and a suspected role for autoimmunity^[@CR7],\ [@CR8]^. Increased levels of glucose, triglycerides, non-esterified FA, cholesterol, ketones, acetate, and β-hydroxybutyrate have been reported in diabetic dogs^[@CR9]^. Further research is required to determine the potential for canines with diabetes to be used as an alternative animal model of human T1D^[@CR10]^, and if metabolomic analysis may identify novel biomarkers of the disease. While metabolomic profiles have been studied in healthy dogs^[@CR11],\ [@CR12]^ and in several disease states, including inflammatory bowel disease^[@CR13]^ and degenerative valvular disease^[@CR14]^, information from an untargeted metabolomics assessment of diabetic dogs is lacking. With this study, we evaluated the metabolomic profiles of fasted diabetic versus healthy control dogs, and hypothesized that diabetic dogs have metabolomic perturbations similar to those reported in human T1D patients, including alterations in carbohydrates, branched-chain AA and FA.

Materials and Methods {#Sec2}
=====================

Study approval and enrollment {#Sec3}
-----------------------------

The study was approved by the University of Florida (UF) Institutional Animal Care and Use Committee (\#201609360) and the Veterinary Hospital Research Review Committee. All experiments were performed in accordance with relevant guidelines and regulations. All dog owners provided written informed consent prior to study enrollment. Dogs with naturally occurring diabetes (n = 6) and control dogs (n = 6) were recruited from the hospital population at the UF Small Animal Hospital. Diabetes was diagnosed prior to study enrollment based on clinical signs (polyuria, polydipsia) in combination with persistent hyperglycemia and glucosuria. Diabetic dogs were included if they were \>1 year of age with body weight \>5 kg, were fasted for a minimum of 12 hours, and if female, were spayed prior to diagnosis of diabetes. Control dogs were deemed healthy based on history and physical exam findings. Control dogs were breed matched to diabetic dogs when possible, and were included if they were \>1 year of age with body weight \>5 kg, received no medications other than monthly flea/tick/heartworm preventatives, and were fasted for a minimum of 12 hours. All dogs were housed with their owners aside from their visit to the Small Animal Hospital.

Sample collection {#Sec4}
-----------------

Time of blood collection was based on patient availability, but all blood samples were collected between 8 am and 4 pm. Blood was collected using a needle and syringe by routine venipuncture and allotted into red top vacutainer tubes containing clot activator. Serum was separated within 30 min of collection and frozen immediately at −80 °C.

Metabolite extraction {#Sec5}
---------------------

Metabolite extraction and analysis from serum was performed as previously described^[@CR15],\ [@CR16]^. Briefly, 100 µL serum aliquots were prepared, and 800 µL of 8:1:1 acetonitrile:methanol:acetone was added to precipitate the proteins. The samples were allowed to cool on ice for 30 minutes before centrifugation to pellet the protein. The supernatant (750 µL) was transferred to a new microcentrifuge tube and dried under a gentle stream of nitrogen. The dried sample was reconstituted in 100 µL of 0.1% formic acid in water for liquid chromatography-mass spectrometry (LC-MS) analysis. LC-MS profiling was performed using a Thermo Q-Exactive Orbitrap mass spectrometer (mass resolution 35,000 at m/z 200) with Dionex UHPLC (ultra-high performance liquid chromatography) and autosampler. Samples were analyzed in a positive and negative heated electrospray ionization as separate injections.

Metabolite analysis {#Sec6}
-------------------

MZmine^[@CR17]^ was used to align, gap-fill, and identify metabolites across the sample set. Known metabolites were identified by matching to an internal retention time library, except in the case of lipids which were identified by fragmentation pathways from MS/MS. Random forest was used to evaluate the classification performance of metabolomics. Analyses were performed using Metaboanalyst 3.0, an open source R-based program specifically designed for metabolomics^[@CR18]^. Values not present in 80% of the data were removed from analysis. Missing values were imputed using k-nearest neighbor, and the data was interquartile range filtered, sum normalized, log2 transformed and autoscaled. All statistical analyses were performed on the combined positive ion and negative ion data sets.

Statistics {#Sec7}
----------

Patient characteristics (Table [1](#Tab1){ref-type="table"}) were compared using Mann-Whitney or Fisher's exact test via GraphPad Prism software v6. Metabolites were compared across the two groups via two-sided t-test, and a heatmap of significantly different features was generated to identify clustering metabolites. P \< 0.05 was considered significant.Table 1Patient Characteristics.GroupBreedAge (years)Median Age (years)Weight (kg)Median Weight (kg)Sex^a^Duration since diagnosis of diabetes (months)Median Disease Duration (months)DiabeticDachshund6.59.757.918.8SF1.54.75Dachshund136.9SF1Miniature schnauzer99.5NM8Labrador retriever13.528.4SF11Labrador retriever10.532.5NM11Mix (Labrador retriever mix)1.328.1NM1HealthyDachshund45.58.819.75SFN/AN/ADachshund115.2SFN/AMiniature schnauzer26.6SFN/ALabrador retriever731.8SFN/ALabrador retriever443.2NMN/AFlat coated retriever830.7NMN/A^a^SF = spayed female; NM = neutered male.

Data availability {#Sec8}
-----------------

The datasets generated and/or analysed during the current study are available from the corresponding author on reasonable request.

Results {#Sec9}
=======

Age (P = 0.29), body weight (P = 0.99) and sex distribution (P = 1.0) were comparable for diabetic and control groups (Table [1](#Tab1){ref-type="table"}). For diabetic dogs, the median duration from diagnosis was 4.75 months (range: 1--11 months). At the time of sample collection, all diabetic dogs were receiving treatment with exogenous insulin but were suspected to have poorly controlled diabetes based on a combination of continued clinical signs of diabetes and the results of blood and/or urine analysis. None of the enrolled animals had ketoacidosis. Controls were breed-matched to diabetic dogs in all but one case (Table [1](#Tab1){ref-type="table"}).

Two hundred known metabolites were detected in positive and negative ion modes from the extracted serum samples. A heat map of known metabolites that differed significantly between diabetic and healthy dogs indicated clustering of the two cohorts (Fig. [1a](#Fig1){ref-type="fig"}). A similar analysis of all detected (unknown and known) metabolites not only enabled classifications based on the entire metabolome, but also improved clustering (Fig. [1b](#Fig1){ref-type="fig"}). The top 50 metabolites that differed significantly between groups are shown in Fig. [1b](#Fig1){ref-type="fig"}. These data demonstrate the ability of metabolomics to classify diabetic and non-diabetic canines.Figure 1Heat map representing (**a**) known metabolites significantly (p \< 0.05) different between diabetic and healthy control dog groups and (**b**) top 50 known and unknown metabolites significantly (p \< 0.05) different between groups. Group is indicated at the top of the figure by red (diabetic, n = 6) or green (healthy, n = 6). Individual dog breed corresponding to column is indicated at the bottom of the figure. Data was sum normalized, log transformed and autoscaled.

The known metabolites identified are categorized by class and/or pathway, direction of change, and fold change in diabetic animals as compared to controls (Table [2](#Tab2){ref-type="table"}). As expected, glycolysis/gluconeogenesis intermediates and sugars were significantly upregulated in the diabetic group, while concentrations of metabolites involved in tryptophan metabolism were downregulated (Table [2](#Tab2){ref-type="table"}). Multiple AA and AA metabolites were significantly lower in the diabetic group, including proline, methionine, histidine, glutamine, and asparagine, while the branched chain AA, valine, was higher. The primary and secondary bile acids, taurochenodeoxycholic acid, taurodeoxycholic acid and tauroursodeoxycholic acid, were significantly lower in diabetic dogs. The lipids lysophosphatidylethanolamine and butyrobetaine were lower in the diabetic group, while 3-hydroxydecanoic acid was higher versus control dogs.Table 2Significant Metabolites and Pathways in Diabetic Dogs.Class/Pathway and Metabolitesp-valueFold change direction (↑ or ↓) and magnitude^a^***Glycolysis/gluconeogenesis intermediates***Glucose/Fructose0.001205↑ 1.36Glucose/Fructose (Cl adduct)0.001314↑ 1.36***Aminosugar and nucleotide sugar metabolism***Glucuronic acid0.00078↑ 1.42Glucosamine/mannosamine0.000371↑ 1.88***Sugars***C~6~H~12~O~6~0.002526↑ 1.50N-acetyl-hexosamine0.0003124↑ 1.75Keto-hexose0.000148↑ 1.86Deoxy-hexose0.000615↓ 0.202-deoxy-D-galactose0.000369↓ 0.32Disaccharide0.016432↑ 2.15***Dipeptide***Carnosine0.007063↑ 1.68***Tryptophan metabolism***Picolinic acid0.004321↓ 0.42Indoxyl sulfate0.004485↓ 0.16Anthranilate (2-aminobenzoic acid)0.000553↓ 0.38***Organic acid and derivatives***5-aminolevulinic acid0.0002224↓ 0.42Alpha-hydroxyisobutyric acid0.009782↑ 4.42***Amino Acids and Metabolites***Proline0.007627↓ 0.66N-acetyl-L-aspartic acid0.000794↓ 0.44N-acetyl-L-aspartic acid (positive ion)0.001863↓ 0.47Methionine0.012396↓ 0.58Methionine sulfoxide0.001815↓ 0.70Valine0.012396↑ 1.27Histidine0.016368↓ 0.77Glutamine0.020218↓ 0.54Creatinine0.021156↓ 0.66Asparagine0.049261↓ 0.78N-acetyl-l-leucine0.022766↓ 0.513-hydroxyphenylacetic acid0.006011↓ 0.56N-formylglycine0.040731↓ 0.74***Bile acids***Taurodeoxycholic acid0.035656↓ 0.07Taurochenodeoxycholic acid0.043389↓ 0.08Tauroursodeoxycholic acid0.005472↓ 0.27***Organoheterocyclic compounds***N-methylnicotinamide0.007934↓ 0.38***Aldehyde***5-hydroxymethyl-2-furaldehyde0.000515↑ 2.03***Benzenoid***Phenethylamine0.028163↓ 0.80***Lipids***LysoPE 18:10.000226↓ 0.343-hydroxydecanoic acid0.02393↑ 1.72Butyrobetaine0.047759↓ 0.77***Microbial origin***Citramalate (fatty acid)0.013703↑ 4.59LL-2,6 diaminoheptanedioate (Diaminopimelic acid) (amino acid)0.049682↓ 0.76***Other Exogenous***Tertbutyl adipic acid0.048648↓ 0.45Hexanesulfonic acid0.011531↓ 0.13^a^↓ indicates downregulation and ↑ indicates upregulation compared with findings in healthy control dogs. Fold change was calculated for diabetic relative to healthy dogs.

Random forest classification showed excellent prediction of group, with 5/6 animals from each group identified correctly and a 16.7% out of bag (OOB) error rate (Table [3](#Tab3){ref-type="table"}). The healthy control dog misclassified to the diabetic group by this method was confirmed to be normoglycemic in both a fasted and fed state 3 months following study enrollment. The random forest importance plot identified 15 metabolites key in classifying the data, with anthranilate, glucose, glucosamine, and lysophosphatidylethanolamine having the most influence in classification (Fig. [2](#Fig2){ref-type="fig"}).Table 3Random Forest Classification into Healthy or Diabetic Dog Groups.Actual GroupPredicted GroupDiabeticHealthyClass Error\*Diabetic510.167Healthy150.167^\*^Overall out of bag (OOB) error rate is 16.7%. Figure 2(**a**) Random forest variable importance plot. Mean decrease accuracy is the measure of the performance of the model without each metabolite. A higher value indicates the importance of that metabolite in predicting group (diabetic vs. healthy). Removal of that metabolite causes the model to lose accuracy in prediction. (**b**) Box and whisker plots of the top four metabolites from (**a**). Data was sum normalized, log transformed and autoscaled.

Discussion {#Sec10}
==========

In this study using an untargeted metabolomic evaluation, we found that the metabolomic profiles differed significantly among fasted diabetic and healthy dogs, with clear clustering of the groups using known and unknown metabolite expression. Based on random forest classification, 5/6 (83%) dogs in each group were classified correctly, an excellent result given the small sample size. The healthy dog that was misclassified as a diabetic dog (Miniature Schnauzer, Fig. [1](#Fig1){ref-type="fig"}) in this analysis was confirmed to be normoglycemic 3 months following the study. This dog displayed upregulated carnosine and downregulated histidine, n-actetyl-L-leucine, and multiple bile acids (similar to diabetic dogs). Possible reasons for this discrepancy include individual variability in metabolomic profiles, environmental or dietary factors, a yet unidentified pre-diabetic state, or other undiagnosed underlying disease.

Studies examining inter- and intra-individual variability in metabolomic profiles in dogs indicate that dog breed is an important factor in metabolomic profile variance in the non-controlled (i.e. home) environment, along with some influence of gender and body weight^[@CR11],\ [@CR19]^. Importantly, in this study, all but two dogs were breed and gender matched and the non-breed matched dogs were body weight matched. The results of this pilot study support future research to expand the scope by increasing the number of dogs examined and implementing a longitudinal design with multiple time points. Moreover, the analytical methods employed have excellent mass accuracy (5 ppm or better) and retention time reproducibility (less than 0.1 min fluctuations), but do not separate all the sugar related species. We also plan to conduct additional studies to identify unknown metabolites with the addition of hydrophilic interaction liquid interaction chromatography (HILIC) to improve separation of sugar related metabolites.

Observed elevations in carbohydrate metabolites and alterations in glycolysis/gluconeogensis metabolites in diabetic dogs were expected and similar to humans with T1D undergoing insulin therapy^[@CR4]^. Similarly, the branched chain AA valine was significantly elevated in diabetic dogs; branched chain AA (valine, leucine, isoleucine) have also been documented to be elevated in humans prior to^[@CR20]^ and after onset of both T1D^[@CR4]^ and type 2 diabetes (T2D)^[@CR21]^ as well as in diabetic NOD (non-obese diabetic) mice^[@CR22]^. However, we report lower N-acetyl-L-leucine in diabetic dogs versus controls while isoleucine was not identified as significantly differing between the groups, representing a potential divergence from human T1D or simply a limitation of the small sample size. The AA methionine was lower in diabetic dogs, similar to children who develop islet AAb at an early age^[@CR3]^ but in contrast to human T1D patients undergoing insulin therapy but with poor glycemic control and reported elevations in this AA^[@CR4]^. Several metabolites in involved in tryptophan metabolism (e.g., anthranilate/2-aminobenzoic acid, picolinic acid, indoxyl sulfate) were lower in diabetic dogs versus healthy controls. This contrasts to reports of increased anthranilic acid in insulin-treated human T1D patients compared to metformin-treated T2D patients and controls without diabetes^[@CR23]^. Further investigation is needed to determine the implications of these findings in dogs, particularly given the importance of anthranilate in the random forest variable importance plot (Fig. [2a](#Fig2){ref-type="fig"}). Although the dogs in this study were receiving insulin, all were undergoing evaluation for poor diabetes control at the time of sample collection. As noted above, some metabolomic alterations in humans with T1D are present in patients regardless of the degree of glycemic control^[@CR4]^. Additional studies comparing dogs with poor glycemic control versus well-controlled diabetic canines are required to determine if this observation holds true in dogs. The metabolomic profiles of untreated diabetic dogs would be expected to have some similarities to dogs with poor glycemic control, along with elevations in ketoacids^[@CR9],\ [@CR24]^. Ketonemia in dogs has been associated only with very low serum insulin concentrations^[@CR9]^, and the insulin doses received by dogs enrolled in this study likely were adequate to prevent significant elevations in ketoacids.

Another interesting finding was the upregulation of carnosine in diabetic dogs compared with control dogs. Carnosine has been shown to inhibit the formation of some advanced glycation end products (AGEs) *in vitro* ^[@CR25]^ and to inhibit glucose- induced production of type IV collagen and fibronectin by podocytes in the kidneys^[@CR26]^. A genetic mutation resulting reduced expression of the carnosinase enzyme that degrades carnosine protects against the development of diabetic nephropathy in human patients^[@CR26]^. While dogs with experimentally induced and naturally occurring diabetes do develop renal glomerular lesions consistent with diabetic nephropathy^[@CR27],\ [@CR28]^, dogs with naturally occurring diabetes do not seem to commonly develop clinically significant diabetic nephropathy^[@CR29],\ [@CR30]^. Although this is speculated to be due to the shorter lifespan of dogs and lack of time for significant renal disease pathology to develop^[@CR29]^, the elevation in carnosine could be relevant. Further study is required to confirm these findings and any relationship to the formation of AGEs in dogs.

Primary and secondary bile acid levels were found to be lower in diabetic dogs, and perturbations in a variety of bile acids have been identified in humans with T1D and T2D^[@CR4],\ [@CR31]^. Bile acids have been recognized as having endocrine functions and are involved in glucose homeostasis^[@CR32]^. Adding to the complexity of bile acid metabolic function is the interplay with the gut microbiota^[@CR33]^, which has recently been shown to be altered in humans and rodents with diabetes^[@CR34]^. In the present study, gut microbiota was not evaluated and the cause of the alterations in bile acids is unknown. Given the important role bile acids play in metabolism, additional investigation is warranted.

In sum, we found that the metabolomic profiles of diabetic dogs differ significantly from healthy non-diabetic dogs. To the authors' knowledge, this study represents the first evaluation of metabolomic profiles in diabetic canines. Both similarities to and differences from metabolic perturbations in humans with diabetes were identified. Further research is needed with increased sample size in a longitudinal study design and, potentially, with a standardized diet to confirm the findings reported herein and identify the underlying mechanisms that contribute to these metabolic changes. Many unknowns still exist with respect to the pathogenesis of canine diabetes, and metabolomic alterations may represent important potential biomarkers to detect diabetes in dogs prior to clinical onset. Indeed, the ability to detect the pre-diabetic state may represent a key component to future discovery in this area^[@CR10]^ and to further define the utility of the dog as a potential model of human T1D.
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